FBI LOGO TM.png
Report [2020-2026] Sickle Cell Disease Treatment Market Size, Share, Growth, Trends, Analysis, Competitive Landscape, Forecast by Fortune Business Insights™
October 13, 2020 07:07 ET | Fortune Business Insights
Pune, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Increasing impetus to research on gene therapy to treat sickle cell disease is a key factor contributing to the global sickle cell disease treatment market,...
Imara-Logo-Color-RGB.jpg
Imara to Present at Upcoming Investor Conferences
September 02, 2020 07:00 ET | Imara, Inc.
BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease
August 25, 2020 07:00 ET | Imara, Inc.
BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Reports Second Quarter 2020 Financial Results and Business Highlights
August 14, 2020 07:00 ET | Imara, Inc.
Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trial Reported Phase 2a interim safety and...
Imara-Logo-Color-RGB.jpg
Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
August 13, 2020 16:01 ET | Imara, Inc.
BOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
August 07, 2020 07:00 ET | Imara, Inc.
BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics Completes $24 Million Private Placement
July 30, 2020 09:00 ET | Cyclerion Therapeutics, Inc.
 - Additional capital to accelerate clinical development of IW-6463 in two CNS indications and olinciguat for sickle cell disease - - IW-6463 translational pharmacology and olinciguat STRONG Phase...
Imara-Logo-Color-RGB.jpg
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
July 30, 2020 07:00 ET | Imara, Inc.
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
June 29, 2020 16:01 ET | Imara, Inc.
BOSTON, June 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Hemex Logo.JPG
Gazelle® Diagnostic Platform, Designed for Low Resource Settings, Integrates Miniaturized Technologies with AI to Transform Disease Screening and Diagnosis
June 17, 2020 03:01 ET | Hemex Health
8-minute, Low-Cost Diagnostic Test for Sickle Cell Disease (SCD) Among First Approved Tests  Includes a One-Minute Malaria Test with Solutions for Other Health Priorities to Follow PORTLAND, Ore. and...